ImmImmupharma Announces Breakthrough Findings into Autoimmune Diseases

ImmuPharma PLC (LSE:IMM), the specialist drug discovery and development company, announces innovative groundbreaking advancements in its preclinical research program focused on P140 and the pathogenesis of autoimmune diseases. This new discovery, conducted by the Company’s R&D subsidiary ImmuPharma Biotech, has yielded compelling data that provides novel insights into autoimmune disease mechanisms.

Importantly for our autoimmune therapy P140, especially for our lead indication in SLE, these findings pave the way for:

• Earlier and more accurate diagnostics
• Identifying patients most likely to respond to P140 therapy
• Improved monitoring of the patient’s response to treatment with P140

Through this research, the company is making a significant step towards personalised medicine in SLE and other autoimmune diseases.

The Company is not at this time releasing detailed data as these findings form part of the ongoing expansion of  our intellectual property portfolio including additional patents for P140.

Commenting on this announcement, Tim McCarthy, CEO of ImmuPharma said: “We are delighted to share these significant findings from ImmuPharma Biotech. This breakthrough research confirms our confidence in P140, its future therapeutic success and also creates new opportunities to strengthen our intellectual property portfolio, positioning us at the forefront of innovation in autoimmune disease therapies.”

Commenting on this announcement, Sébastien Goudreau, CEO of ImmuPharma Biotech said: “The findings we have announced today highlight the extremely diligent and focused research we have been conducting behind the scenes at Immupharma Biotech in order to better characterise and explain our lead asset P140 and its application in autoimmune diseases, which is now gaining significant attention within the biopharmaceutical industry.”

To download post click here